Safety and effectiveness assessment of 2011–2012 seasonal influenza vaccine produced in China: a randomized trial
- 5 September 2017
- journal article
- research article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 129 (8) , 907-914
Abstract
Objective: This study evaluated the effectiveness and safety of the egg-based, trivalent, inactivated split influenza vaccine produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, China. Methods: From March 2012 through May 2012, we enrolled a total of 1390 healthy volunteers between the ages of 3 and 80 years in a randomized clinical trial at the Hebei Disease Control Center Vaccine Clinical Evaluation Center. For all subjects, body part adverse reactions and whole-body adverse reactions were observed 30 min, 6 h, and 1–7 days’ post-inoculation. If no severe adverse effects were observed 7 days’ post-vaccination, the local and systemic reactions of preliminary test participants were recorded until day 28. There was no placebo group in this study. Blood samples were taken for serological testing before vaccination and 28 days’ post-vaccination. Results: Twenty-eight days after vaccination, the seroconversion rates of experimental and control groups were H1N1 75.3% and 75.7%, H3N2 75.8% and 71.8%, B 70.7% vs. 69.4%, (P > 0.05). The antibody Geometric Mean Titer(GMT)of experimental and control groups were H1N1 (179.7, 182.4), H3N2 (584.0, 445.7), B (201.4,191.6). The protection rate of experimental and control groups was not statistically significant (H1N1: 86% vs. 87%, H3N2: 99% vs. 98%, B: 98% vs. 98%). Also, 95% confidence intervals of the protection rate difference between the experimental and the control group were H1N1: −0.1% (−4.1,3.8) %, H3N2: 0.3% (−1.0,1.7) % and B: 0.2% (−1.5,1.9) %; confidence intervals exceeded the limit of −5%. The rates of adverse reactions between experimental and control groups were 6.3% and 7.7% in local response reactions, and 19.5% and 18.0% in systemic reactions. Three hundred and twenty-seven adverse events (AEs) in 1200 (27.76%) subjects were reported within 28 d after vaccination. No serious adverse events occurred during the study. Conclusions: The experimental vaccine three-antibody protection rate was non-inferior to the control vaccine. Our results demonstrated that the experimental vaccine achieved the primary immunogenic end point of the intended clinical protocol, as well as a secondary immunogenic end-point, with an acceptable level of safety. IRB approval for this study was issued under #2012Y0005 and registered as Clinical Trial No. NCT01551810.Keywords
Funding Information
- Selection Influenza Virus Cold Adapted Strain in Vero Cell, and Study on the Gene Loci Related Low Temperature Adaptation (2010CD134)
- Cells of Influenza Virus Attenuated Vaccine (2011DFR30420)
- Research on Genes Related to Adaptation of Influenza Virus in Vero Cell (2013FZ141)
- Medical Science and Technology Innovation Project of Chinese Academy of Medical Sciences (2016-I2M-1-019)
- Vero Cells of Influenza Virus Attenuated Vaccine Development (2013ZX10004003-003-002)
- Research on the key technology of influenza virus vaccine demonstration and Industrialization (2014AE008)
- The Key Technology and Product Development of Vero Cells Pandemic Influenza Vaccine (2012AA02A404-7)
This publication has 5 references indexed in Scilit:
- Seasonal Influenza Vaccine Effectiveness among Children Aged 6 to 59 Months in Southern ChinaPLOS ONE, 2012
- Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010)Vaccine, 2011
- Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) VaccineNew England Journal of Medicine, 2006
- Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adultsVaccine, 2001
- Role of Hemagglutinin Cleavage for the Pathogenicity of Influenza VirusVirology, 1999